ADVFN - Advanced Financial Network.
HOME» NYSE » B » BEC Stock Price » BEC Stock News

Beckman Coulter Share News

 Beckman Coulter, Inc. Stock Price
BEC Stock Price
 Beckman Coulter, Inc. Stock Chart
BEC Stock Chart
 Beckman Coulter, Inc. Stock News
BEC Stock News
 Beckman Coulter, Inc. Company Information
BEC Company Information
 Beckman Coulter, Inc. Stock Trades
BEC Stock Trades

PerkinElmer Isn't For Sale, CEO Says; Shares Slide

By Caitlin Nish Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- PerkinElmer Inc. (PKI) isn't for sale, its chief executive said Friday, disputing reports that sent its stock up 6.9% Thursday. "Media reports containing speculation to the effect that PerkinElmer is for sale, or positioning itself for sale, are inaccurate," CEO Robert Friel said in a statement. "A sale of the company is not being discussed, and such a transaction is not in the company's strategic plans." Shares of PerkinElmer, which sells analytical products and services to the health-care and industrial sectors, slid 3.6% in recent trading to $26.72. They are up 19% in the past year. Friel was responding to reports Thursday suggesting the company was considering pursuing a large acquisition or putting itself up for sale after making an unsuccessful attempt for medical-test maker Beckman Coulter Inc. (BEC). Danaher Corp. (DHR) earlier this month agreed to acquire Beckman Coulter for $5.87 billion, ending two months of speculation about the future of Beckman, which endured a rough year last year following the recall of a faulty test for heart problems, multiple financial-guidance cuts and an unexpected CEO resignation. "We continue to be on strategy with regard to our plans for growth, and we remain in strong financial health," Friel said. "PerkinElmer remains committed to growing our business and leveraging the strong foundation we've already built to achieve future growth," he added. PerkinElmer reported at the beginning of this month that its fourth-quarter earnings soared as it booked a $315.3 million gain on the disposition of discontinued operations. It saw growth in both its environmental-health division and human-health division, with revenue up 8% and 12%, respectively. -By Caitlin Nish, Dow Jones Newswires; 212-416-2076; caitlin.nish@dowjones.com --Jon Kamp and Lauren Pollock contributed to this article.

Stock News for Beckman Coulter (BEC)
DateTimeHeadline
06/28/201113:48:41CORRECT:Danaher In Market With Offering To Help Fund Acquisition
06/17/201104:07:36EU Clears US Technology Firm Danaher To Buy Beckman Coulter
04/18/201111:54:16Beckman Coulter Delays FDA Filings For Key Heart Test To 3Q
02/25/201112:38:49PerkinElmer Isn't For Sale, CEO Says; Shares Slide
02/24/201111:44:18PerkinElmer, After Beckman-Bid Loss, Is Mulling Deals -Bloomberg
02/07/201116:48:21Beckman Deal Moves Danaher Deeper Into Technology Sector
02/07/201108:14:50Danaher Agrees To Acquire Beckman Coulter For $5.87 Billion
01/28/201114:25:16KKR Said To Drop Out Of Beckman Coulter Bid Group -Bloomberg
07/06/201015:19:05FDA Warns Beckman Coulter On Marketing Of "AccuTnI" Heart Test
05/14/201009:52:56Beckman Coulter Expects First Half 2011 Troponin Filing
12/17/200917:11:22Beckman Coulter Targets Mid-Teens Earnings Growth In 2010

Beckman Coulter and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad